Jessicca Rege serves as Vice President, Clinical Research Oncology at Alkermes, where she is responsible for establishing the company’s immuno-oncology development strategy and overseeing the execution of its global clinical trials. Dr. Rege joined Alkermes in 2020, bringing with her more than 15 years of experience in research, clinical development and global medical affairs. She previously held roles of increasing responsibility at Bristol-Myers Squibb, Eisai, Daichi Sankyo and Boehringer Ingelheim. Dr. Rege earned a Bachelor of Science from Carson-Newman, and holds both a Master of Science in Physiology and a Ph.D. in Pharmaceutical Sciences from Virginia Commonwealth University. She completed her postdoctoral fellowship in pediatric leukemia at the University of Pennsylvania’s Children’s Hospital of Philadelphia